Abstract
Eisai currently ranks 18th of all researched-based companies in terms of
pharmaceutical sales. This report provides a full review of the company's
activities together with sales forecasts for key products to 2010.
From April to September 2005, Eisai's net sales were ¥282,629 million, an 8%
increase over the previous fiscal year's interim period, due to a rise in
sales of Aricept (+18% to ¥89,991 million) and Pariet (+10% to ¥71,576
million). Pharmaceutical sales improved by 9% to ¥272,371 million. Operating
income was up by 9% to ¥45,269 million, and net income also advanced by 9% to
¥30,158 million. Expenditure on R&D increased by 19% to ¥44,400 million.
Geographical sales were as follows: Japan (+4% to ¥139,576 million), North
America (+11% to ¥113,958 million), Europe (+10% to ¥21,198 million) and Asia
and others (+37% to ¥7,897 million) reflecting the fact that Eisai is less
reliant on the Japanese domestic market than its competitors.
R&D Pipeline Overview
- E2007 is an oral AMPA type glutamate receptor antagonist,
undergoing multiple Phase II trials targeted at Parkinson's disease and
multiple sclerosis in Europe and epilepsy (US/Europe). Filing for epilepsy in
the US is expected 2007.
- E7389 is a synthetic analogue of halichondrin B (HB), a natural
product shown, in preclinical studies, to have highly potent anticancer
activity in vitro and in vivo. Phase II studies started in the US in 2004, and
filings are expected in 2007.
Major Products Forecast to 2010
- Aricept (CNS)
- Methycobol (CNS)
- Pariet (Gastrointestinal)
- Selbex (Gastrointestinal)
- Glakay (Osteoporosis)
- Iomeron (Contrast agent)
- Myonal (CNS)
- Azeptin (Anti-allergenic)
- Nitrol-R (Cardiovascular)
| 
View Cart
